News

Latuda, the antipsychotic agent, has been marketed for the treatment of schizophrenia in Canada by Sunovion Pharmaceuticals Canada, a subsidiary of the US-based Sunovion Pharmaceuticals. The company said

Novaliq claims that CyclASol is the first and only 0.05% clear cyclosporin solution, which is available in multi-dose and preservative free bottles to treat dry eye syndrome. Developed

The MAA validation confirms that the submission is sufficiently complete to start the formal review process. The EMA’s review of the MAA will follow the centralized marketing authorization

Currently, the company is evaluating the safety and efficacy of eravacycline in a Phase III clinical program, which includes two trials. The IGNITE 1 trial is assessing the

NiaCel is one of the first commercially available products to feature the ingredient NIAGEN from ChromaDex (CDXC), an innovative natural products company that provides proprietary ingredients and science-based

The PD-1 pathway (programmed cell death) is being actively pursued by most of the big pharmaceutical companies due to its critical role as a checkpoint in our immune

This patent provides Mersana broad coverage for its polymer-based Fleximer-ADC platform technology. The patent covers Fleximer-drug conjugates that can be linked to an antibody to create next-generation antibody

In the US, Canada, Japan and Russia, simeprevir is approved to treat genotype 1 HCV as part of an antiviral treatment regimen in combination with pegylated interferon and

The company secured the certification for its new supplement format designed specifically for children called Kidi Bites. Anlit Marketing VP Shai Karlinski said the company approached this certification